- Home
- FEMY vs SABS Comparison
FEMY vs SABS Comparison
Compare FEMY & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- SABS
- Stock Information
- Founded
- FEMY 2004
- SABS 2014
- Country
- FEMY United States
- SABS United States
- Employees
- FEMY N/A
- SABS N/A
- Industry
- FEMY Medical/Dental Instruments
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- SABS Health Care
- Exchange
- FEMY Nasdaq
- SABS Nasdaq
- Market Cap
- FEMY 27.2M
- SABS 23.9M
- IPO Year
- FEMY 2021
- SABS N/A
- Fundamental
- Price
- FEMY $1.09
- SABS $4.65
- Analyst Decision
- FEMY Strong Buy
- SABS Strong Buy
- Analyst Count
- FEMY 3
- SABS 5
- Target Price
- FEMY $10.00
- SABS $12.40
- AVG Volume (30 Days)
- FEMY 185.8K
- SABS 94.9K
- Earning Date
- FEMY 11-12-2024
- SABS 11-06-2024
- Dividend Yield
- FEMY N/A
- SABS N/A
- EPS Growth
- FEMY N/A
- SABS N/A
- EPS
- FEMY N/A
- SABS N/A
- Revenue
- FEMY $1,260,643.00
- SABS $1,512,723.00
- Revenue This Year
- FEMY $157.75
- SABS N/A
- Revenue Next Year
- FEMY $254.07
- SABS N/A
- P/E Ratio
- FEMY N/A
- SABS N/A
- Revenue Growth
- FEMY 15.33
- SABS N/A
- 52 Week Low
- FEMY $0.73
- SABS $2.16
- 52 Week High
- FEMY $2.40
- SABS $7.70
- Technical
- Relative Strength Index (RSI)
- FEMY 46.31
- SABS 63.47
- Support Level
- FEMY $1.05
- SABS $3.32
- Resistance Level
- FEMY $1.24
- SABS $4.30
- Average True Range (ATR)
- FEMY 0.08
- SABS 0.62
- MACD
- FEMY -0.00
- SABS 0.07
- Stochastic Oscillator
- FEMY 16.00
- SABS 84.07
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.